Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects

Bozorgi, Azam; Bozorgi, Maryam; Khazaei, Mozafar

doi:10.1007/s13402-022-00700-w

Cited by 10 publications

(4 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to the constant threat of developing cytokine release syndrome (CRS) and early relapse of antigen-positive leukemia (loss of active CAR T cell-mediated surveillance) or later relapse (loss of antigen) of the tumor, limited the range of specific CAR T cells [175]. However recent cotreatment of CAR T cells with immunomodulators (immune check point inhibitors like PDL1-PD1 blockage) has shown to be promising in terms of the depth and durability of the treatment clinically [176][177][178][179]. The above description insights us into the importance of the 'CSC-TME-immune' triangular (Fig.…”

Section: Cscs Control the Host Immune System And Mediate Drug Resistancementioning

confidence: 99%

Unveiling the mechanisms and challenges of cancer drug resistance

Khan,

Fatima,

Aisha

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer treatment strategies are evolving due to innate and acquired resistance capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells to survive and progress under unfavorable conditions. Although the mechanism of drug resistance is being widely studied to generate new target-based drugs with better potency than existing ones. However, due to the broader flexibility in acquired drug resistance, advanced therapeutic options with better efficacy need to be explored. Combination therapy is an alternative with a better success rate though the risk of amplified side effects is commonplace. Moreover, recent groundbreaking precision immune therapy is one of the ways to overcome drug resistance and has revolutionized anticancer therapy to a greater extent with the only limitation of being individual-specific and needs further attention. This review will focus on the challenges and strategies opted by cancer cells to withstand the current therapies at the molecular level and also highlights the emerging therapeutic options -like immunological, and stem cell-based options that may prove to have better potential to challenge the existing problem of therapy resistance.

show abstract

Section: Cscs Control the Host Immune System And Mediate Drug Resistancementioning

confidence: 99%

Unveiling the mechanisms and challenges of cancer drug resistance

Khan,

Fatima,

Aisha

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…M2 macrophages, on the other hand, activated by IL-4, IL-10, and IL-13, promote tumor growth and suppress anti-tumor immune responses [ 129 ]. TAMs suppress T-cells by secreting factors such as IL-10, ARG1, iNOS, PGE2, and TGFβ and recruiting T regs [ 165 , 166 , 167 ]. TAMs can also express PD-L1, CD80/86, or death receptor ligands that engage with inhibitory receptors on effector cells [ 166 ].…”

Section: Overcoming the Tumor Microenvironmentmentioning

confidence: 99%

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

Chamorro,

Somes,

Hoyos

2023

Cancers

View full text Add to dashboard Cite

Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presents an in-depth analysis of engineered adoptive T-cell therapies (E-ACTs), an innovative frontier in cancer immunotherapy, focusing on their application in breast cancer. We explore the evolving landscape of chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies, highlighting their potential and challenges in targeting breast cancer. The review addresses key obstacles such as target antigen selection, the complex breast cancer tumor microenvironment, and the persistence of engineered T-cells. We discuss the advances in overcoming these barriers, including strategies to enhance T-cell efficacy. Finally, our comprehensive analysis of the current clinical trials in this area provides insights into the future possibilities and directions of E-ACTs in breast cancer treatment.

show abstract

“…Folate receptor, MUC1, c-Met, integrin, HER2, ROR1, and TEM8 are among the targeted receptors in breast cancer in recent studies [ 181 ]. Several recent publications have reviewed the advancements of this approach in breast cancer [ 182 , 183 , 184 , 185 , 186 , 187 ].…”

Section: The Unchartedmentioning

confidence: 99%

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

Montazeri Aliabadi,

Manda,

Sidgal

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Breast cancer became the most diagnosed cancer in the world in 2020. Chemotherapy is still the leading clinical strategy in breast cancer treatment, followed by hormone therapy (mostly used in hormone receptor-positive types). However, with our ever-expanding knowledge of signaling pathways in cancer biology, new molecular targets are identified for potential novel molecularly targeted drugs in breast cancer treatment. While this has resulted in the approval of a few molecularly targeted drugs by the FDA (including drugs targeting immune checkpoints), a wide array of signaling pathways seem to be still underexplored. Also, while combinatorial treatments have become common practice in clinics, the majority of these approaches seem to combine molecularly targeted drugs with chemotherapeutic agents. In this manuscript, we start by analyzing the list of FDA-approved molecularly targeted drugs for breast cancer to evaluate where molecular targeting stands in breast cancer treatment today. We will then provide an overview of other options currently under clinical trial or being investigated in pre-clinical studies.

show abstract

Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects

Cited by 10 publications

References 199 publications

Unveiling the mechanisms and challenges of cancer drug resistance

Unveiling the mechanisms and challenges of cancer drug resistance

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

Contact Info

Product

Resources

About